Abstract
Background: In spite of increasing number of chemotherapeutic drugs, achieving chemotherapy drug with minimal side effects in cancer treatment is still a major challenge. Chemotherapy has an important role in the treatment of non- Hodgkin's lymphoma cancer. Chlorambucil (CBL) is a lipophilic DNA alkylating drug having been administrated in many cancers like leukemia but its use has been limited because of chemical instability, low permeability of the cells and high toxicity.
Objective: The main aim of this study is improving in vitro anticancer activity of CBL through conjugating CBL with Poly (DL-lactide-co-glycolide) (PLGA). The characterization of physiochemical structure of PLGA-CBL conjugation was determined by different techniques such as dynamic light scattering (DLS), Scanning electron microscopy (SEM), Atomic force microscopy (AFM), Fourier transform infrared spectroscopy (FTIR), and HNMR Spectrometry. Moreover, therapeutic effect of new PLGA-CBL conjugated was evaluated, after which, the cell viability was determined by MTT assay and the numbers of apoptotic/necrotic cells were calculated by flowcytometry using Annexin V/PIkit on a non- Hodgkin's lymphoma cell line. Results and Conclusion: The results of in vitro cytotoxicity showed significantly greater conjugated PLGA-CBL on the non-Hodgkin's lymphoma compared to CBL aloneKeywords: Non-hodgkin's lymphoma, PLGA, chlorambucil, nanoparticles, XTT, in vitro.
Graphical Abstract
Article Metrics
20
3